Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

about

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.

P2860

Q55176938-1EBCC576-36E8-4E0C-9E3A-342194A33EAB

P2860

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

Item

http://www.wikidata.org/entity/Q38990518

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Dynamic population pharmacokin ...... daily dosing of canagliflozin.

@en

type

Item

label

Dynamic population pharmacokin ...... daily dosing of canagliflozin.

@en

prefLabel

Dynamic population pharmacokin ...... daily dosing of canagliflozin.

@en

P1476

Dynamic population pharmacokin ...... daily dosing of canagliflozin.

@en

P2093

Adrian Dunne

http://www.w3.org/2001/XMLSchema#string

Chyi-Hung Hsu

http://www.w3.org/2001/XMLSchema#string

Damayanthi Devineni

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Jose Pinheiro

http://www.w3.org/2001/XMLSchema#string

Willem de Winter

http://www.w3.org/2001/XMLSchema#string

Xavier Woot de Trixhe

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

The Concise Guide to PHARMACOLOGY 2015/16: Transporters

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

The global burden of diabetes and its complications: an emerging pandemic.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review.

Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis.

P304

1072-1081

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13180

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28138980

http://www.w3.org/2001/XMLSchema#string

P921

glycosylation

P932

5401970

http://www.w3.org/2001/XMLSchema#string

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

about

P2860

P2860

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932